Analysts Set TuHURA Biosciences, Inc. (NASDAQ:HURA) Target Price at $12.67

Shares of TuHURA Biosciences, Inc. (NASDAQ:HURA) have earned an average rating of “Buy” from the five ratings firms that are presently covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $12.67.

A number of research firms have weighed in on HURA. Brookline Capital Management upgraded TuHURA Biosciences to a “strong-buy” rating in a report on Monday. HC Wainwright reiterated a “buy” rating and set a $12.00 price objective on shares of TuHURA Biosciences in a report on Friday, May 16th. Finally, Wall Street Zen lowered TuHURA Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, June 14th.

Institutional Investors Weigh In On TuHURA Biosciences

Institutional investors have recently modified their holdings of the business. Accent Capital Management LLC purchased a new position in TuHURA Biosciences in the 4th quarter valued at about $29,000. TT Capital Management LLC purchased a new position in TuHURA Biosciences in the 4th quarter valued at about $41,000. Jefferies Financial Group Inc. purchased a new position in TuHURA Biosciences in the 4th quarter worth approximately $54,000. Bank of America Corp DE purchased a new position in TuHURA Biosciences in the 4th quarter worth approximately $59,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in TuHURA Biosciences in the 4th quarter worth approximately $61,000. 0.62% of the stock is currently owned by institutional investors and hedge funds.

TuHURA Biosciences Price Performance

Shares of NASDAQ HURA opened at $2.29 on Tuesday. The business’s 50 day moving average is $3.31 and its two-hundred day moving average is $3.69. TuHURA Biosciences has a 1-year low of $1.80 and a 1-year high of $7.93.

TuHURA Biosciences (NASDAQ:HURA) last released its earnings results on Thursday, May 15th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02).

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.